- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Biogen Receives $205.31 Average Price Target from Analysts
Biogen stock assigned 'Hold' rating by 28 brokerages covering the company
Mar. 27, 2026 at 7:18am
Got story updates? Submit your updates here. ›
Shares of Biogen Inc. (NASDAQ:BIIB) have been assigned a consensus 'Hold' rating from 28 brokerages currently covering the company, with an average 1-year price target of $205.31. The ratings include one 'Sell' recommendation, 15 'Hold' recommendations, and 12 'Buy' recommendations.
Why it matters
Biogen is a major biotechnology company focused on developing treatments for neurological and neurodegenerative diseases. The consensus rating and price target from analysts provide insight into the current market sentiment and outlook for the company's stock performance.
The details
The analysts' ratings and price targets reflect a mixed view on Biogen's prospects. While a majority of analysts have a 'Hold' or 'Buy' recommendation, there is also a 'Sell' rating, indicating some uncertainty about the company's future. The average price target of $205.31 represents potential upside of around 7% from the stock's current trading price.
- The analyst ratings and price targets were issued within the last year.
The players
Biogen Inc.
A multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases, headquartered in Cambridge, Massachusetts.
Citigroup
A global investment bank that raised its price target on Biogen shares from $185 to $215 and maintained a 'Neutral' rating.
Jefferies Financial Group
An investment banking firm that increased its target price on Biogen from $190 to $210 and reiterated a 'Buy' rating.
Wedbush
A financial services firm that raised its price target on Biogen from $178 to $187 and kept a 'Neutral' rating on the stock.
Barclays
A multinational investment bank that initiated coverage on Biogen with an 'Equal Weight' rating and a $185 price target.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee
The takeaway
The mixed analyst views on Biogen's stock reflect the challenges and uncertainties facing the company as it navigates the competitive biopharmaceutical landscape. Investors will be closely watching Biogen's future product development and financial performance to gauge the company's long-term prospects.
